Last reviewed · How we verify
Blood and adrenaline
This drug stimulates the release of adrenaline and increases blood flow to vital organs.
This drug stimulates the release of adrenaline and increases blood flow to vital organs. Used for Cardiogenic shock.
At a glance
| Generic name | Blood and adrenaline |
|---|---|
| Also known as | Epinephrine, Blood |
| Sponsor | International Centre for Diarrhoeal Disease Research, Bangladesh |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
The exact mechanism of action is not fully understood, but it is believed to stimulate the sympathetic nervous system, leading to increased heart rate and blood pressure. This can help to improve blood flow to vital organs, such as the brain and heart, in situations where it is compromised.
Approved indications
- Cardiogenic shock
Common side effects
- Hypertension
- Tachycardia
- Headache
- Nausea
- Vomiting
- Dizziness
- Palpitations
- Anxiety
- Insomnia
- Fatigue
Key clinical trials
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- Positioning of Molecular Markers in Clinical Routine for the Management of Patients With Adrenal Cancers/Tumors (COMETE-CARE) (NA)
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (PHASE2)
- A Study to Find the Highest Dose of SNDX-5613 (Revumenib) as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, and Mixed Phenotype Acute Leukemia (PHASE1)
- Polycystic Ovary Syndrome in Type 1 Diabetes
- Antibiotyping and Prevalence of Virulent Genotypes Among Helicobacter Pylori and Their Impact on Response to Therapy (NA)
- Neuroendocrine Response in Pediatric Febrile Seizures
- Prevalence of Hypoglycaemia in Congenital Adrenal Insufficiency (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: